Clinical Chemistry and Laboratory Medicine (CCLM)
Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Editor-in-Chief: Plebani, Mario
Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.
IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition
SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238
Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease
1Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University of Frankfurt, Frankfurt, Germany
Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 49, Issue 3, Pages 367–374, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2011.087, February 2011
- Published Online:
A growing body of evidence suggests that Alzheimer's disease (AD) is a multifactorial disease resulting in the well-known, common neuropathological pathway characterized by extracellular fibrillar β amyloid (Aβ) deposits in the brain, intracellular neurofibrillary tangles (NFT) and neuronal as well as axonal degeneration. While fairly accurate, the clinical diagnosis of probable AD based on standard diagnostic criteria does not take into account the long preclinical and prodromal course of AD. AD-related pathophysiological changes can occur many years and even decades before the appearance of clinical dementia syndrome. Biomarkers that are related to the pathophysiology of AD may thus help detect the preclinical stages of disease, and improve early and differential diagnosis. Here, we provide an overview of current literature on the core AD biomarkers, Aβ and phosphor-tau (p-tau), on different methods and modalities of assessing them [e.g., cerebrospinal fluid (CSF) analysis and PET imaging], and on their diagnostic and predictive value in preclinical and clinical stages of AD.
Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.